Xenon Pharmaceuticals (XENE) EBT (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of EBT data on file, last reported at -$104.9 million in Q1 2026.

• On a quarterly basis, EBT fell 62.29% year-over-year to -$104.9 million in Q1 2026; TTM through Mar 2026 was -$391.3 million, a 53.15% decrease from a year earlier, with the FY2025 full-year figure at -$351.1 million, down 47.25% from the prior year.
• EBT for Q1 2026 stood at -$104.9 million, up from -$110.9 million in the prior quarter.
• Over the last five years, EBT for XENE reached as high as -$20.1 million in Q1 2022 and fell as low as -$110.9 million in Q4 2025.
• Historically, EBT has averaged -$59.0 million across 5 years, with a median of -$48.6 million in 2023.
• Across the five-year window, EBT slumped 141.13% in 2022 and declined 14.68% in 2024, its largest moves.
• Year by year, EBT stood at -$36.3 million in 2022, then dropped by 23.97% to -$44.9 million in 2023, then sank by 54.7% to -$69.5 million in 2024, then sank by 59.48% to -$110.9 million in 2025, then gained by 5.43% to -$104.9 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$104.9 million in Q1 2026, -$110.9 million in Q4 2025, and -$90.2 million in Q3 2025.